the efficacy data do not clearly show that PTH should be selected over antiresorptive therapies for the treatment of osteoporosis. In addition, PTH is expensive and must be administered daily via ...

2008;4(9):514-523. Whether patients with high bone-turnover rates will derive most benefit from treatments that reduce bone resorption and turnover (and vice versa for patients with low bone ...

“It's sort of a combination of an antiresorptive and an anabolic [bone ... And because osteoporosis is a chronic condition, it takes longer to show treatment effect, which requires longer ...

investigated the effect of endogenous PTHrP on the therapeutic efficacy of PTH 1–34, to explore the molecular mechanisms that mediate the anabolic ... PTH in the treatment of osteoporosis ...

One growth driver is the increasing adoption of expensive anabolic therapies. The osteoporosis market is forecasted to grow from $10.5b in 2023 to $17.9b by 2033 at a compound annual growth rate ...

NaQuinate is under clinical development by Haoma Medica and currently in Phase I for Osteoporosis. According to GlobalData, Phase I drugs for Osteoporosis have a 65% phase transition success rate ...